CETP (Cholesteryl Ester Transfer Protein) Inhibition With Anacetrapib Decreases Production of Lipoprotein(a) in Mildly Hypercholesterolemic Subjects | Zendy

Tiffany Thomas | Zendy; Haihong Zhou | Zendy; Wahida Karmally | Zendy; Rajasekhar Ramakrishnan | Zendy; Stephen Holleran | Zendy; Yang Liu | Zendy; Patricia Jumes | Zendy; John A. Wagner | Zendy; Brian K. Hubbard | Zendy; Stephen F. Previs | Zendy; Thomas P. Roddy | Zendy; Amy O. JohnsonLevonas | Zendy; David E. Gutstein | Zendy; Santica M. Marcovina | Zendy; Daniel J. Rader | Zendy; Henry N. Ginsberg | Zendy; John S. Millar | Zendy; Gissette ReyesSoffer | Zendy

Open Access

CETP (Cholesteryl Ester Transfer Protein) Inhibition With Anacetrapib Decreases Production of Lipoprotein(a) in Mildly Hypercholesterolemic Subjects

Author(s) -

Tiffany Thomas,

Haihong Zhou,

Wahida Karmally,

Rajasekhar Ramakrishnan,

Stephen Holleran,

Yang Liu,

Patricia Jumes,

John A. Wagner,

Brian K. Hubbard,

Stephen F. Previs,

Thomas P. Roddy,

Amy O. JohnsonLevonas,

David E. Gutstein,

Santica M. Marcovina,

Daniel J. Rader,

Henry N. Ginsberg,

John S. Millar,

Gissette ReyesSoffer

Publication year - 2017

Publication title -

arteriosclerosis thrombosis and vascular biology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.007

H-Index - 270

eISSN - 1524-4636

pISSN - 1079-5642

DOI - 10.1161/atvbaha.117.309549

Subject(s) - cholesterylester transfer protein , chemistry , lipoprotein , pharmacology , medicine , cholesterol , biochemistry

Lp(a) [lipoprotein (a)] is composed of apoB (apolipoprotein B) and apo(a) [apolipoprotein (a)] and is an independent risk factor for cardiovascular disease and aortic stenosis. In clinical trials, anacetrapib, a CETP (cholesteryl ester transfer protein) inhibitor, causes significant reductions in plasma Lp(a) levels. We conducted an exploratory study to examine the mechanism for Lp(a) lowering by anacetrapib.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research